Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013)
Vericel's (VCEL) quarterly Preferred Stock Liabilities came in at $42.9 million in Q2 2013, up 13.76% year-on-year from $37.7 million in Q2 2012, and little changed quarter-over-quarter from $42.9 million in Q1 2013.
Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends
Vericel has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $42.9 million for Q2 2013.
- Preferred Stock Liabilities for Q2 2013 came in at $42.9 million, up 13.76% year-over-year; the trailing twelve-month figure through Jun 2013 was $42.9 million (up 13.76% YoY), and the FY2012 annual result was $41.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $42.9 million for Q2 2013 at Vericel, roughly flat from $42.9 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $42.9 million in Q1 2013 to a low of $37.7 million in Q2 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 42.88 Mn |
| Mar 31, 2013 | 42.88 Mn |
| Dec 31, 2012 | 41.61 Mn |
| Sep 30, 2012 | 40.36 Mn |
| Jun 30, 2012 | 37.69 Mn |